Medications

FDA approves first targeted therapy for HER2-low breast cancer

The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...

Oncology & Cancer

Updated recommendations for managing hereditary breast cancer

(HealthDay)—One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant ...

page 1 from 8